Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.

Marina Maria Vieira de Figueiredo CaldasKesley Pablo Morais de AzevedoAna Clara de França NunesVictor Hugo de OliveiraIsac Davidson Santiago Fernandes PimentaIsabela Dantas Torres de AraújoFrancisco Alves Bezerra NetoAna Katherine da Silveira Gonçalves de OliveiraGrasiela Piuvezam

Published in: Advances in rheumatology (London, England) (2021)

Rituximab is a promising strategy for the SSc-associated ILD and cutaneous fibrosis treatment. PROSPERO registration number: CRD42019132018.

Keyphrases

systemic sclerosis
interstitial lung disease
diffuse large b cell lymphoma
hodgkin lymphoma
chronic lymphocytic leukemia
rheumatoid arthritis
idiopathic pulmonary fibrosis
combination therapy